ImmuCell Corp.

{
  "main_header": {
    "sid": 1155880,
    "name": "ImmuCell Corp.",
    "stock_name": "ImmuCell Corp.",
    "full_name": "ImmuCell Corp.",
    "name_url": "stocks-analysis/immucell-corp",
    "exchange": 1,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "6.11",
    "chg": -0.31,
    "chgp": "-4.86%",
    "dir": -1,
    "prev_price": "6.42",
    "mcapval": "61.51",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US4525253062",
    "curr_date": "Feb 05",
    "curr_time": "",
    "bse_nse_vol": "20.78 k",
    "exc_status": "Active",
    "traded_date": "Feb 05, 2026",
    "traded_date_str": "2026 02 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/immucell-corp-1155880-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ImmuCell Corp. Experiences Valuation Adjustment Amidst Strong Yearly Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/immucell-corp-sees-valuation-grade-shift-from-attractive-to-expensive-amid-price-decline-3686211",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ImmuCellCorp_valuationdot_3686211.png",
        "date": "2025-11-10 15:41:35",
        "description": "ImmuCell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation, currently priced at $6.10. Over the past year, it achieved a 72.80% return, significantly outperforming the S&P 500. However, the company remains loss-making, with negative returns on capital and equity."
      }
    ],
    "total": 11,
    "sid": "1155880",
    "stock_news_url": "https://www.marketsmojo.com/news/immucell-corp-1155880"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

ImmuCell Corp. Experiences Valuation Adjustment Amidst Strong Yearly Performance Metrics

2025-11-10 15:41:35

ImmuCell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation, currently priced at $6.10. Over the past year, it achieved a 72.80% return, significantly outperforming the S&P 500. However, the company remains loss-making, with negative returns on capital and equity.

Read full news article

View All News